Investigational HIV integrase inhibitors in phase I and phase II clinical trials. (Q47909110)

6 February 2018

title

Investigational HIV integrase inhibitors in phase I and phase II clinical trials. (English)

1 reference

6 February 2018

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

3

Mark A Wainberg

1 reference

6 February 2018

Thibault Mesplède

series ordinal

2

object named as

Thibault Mesplède

1 reference

6 February 2018

author name string

Yingshan Han

series ordinal

1

1 reference

6 February 2018

language of work or name

English

0 references

publication date

28 September 2017

1 reference

6 February 2018

Expert Opinion on Investigational Drugs

published in

1 reference

6 February 2018

volume

26

1 reference

6 February 2018

page(s)

1207-1213

1 reference

6 February 2018

issue

11

1 reference

6 February 2018

Allosteric inhibition of HIV-1 integrase activity

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Targeting Virus-host Interactions of HIV Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Formulation and pharmacology of long-acting cabotegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

The promise and pitfalls of long-acting injectable agents for HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Cabotegravir long-acting for HIV-1 prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Differential sensitivities of retroviruses to integrase strand transfer inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Integrase strand transfer inhibitors in the management of HIV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1378643

10.1080/13543784.2017.1378643

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

28956664

1 reference

6 February 2018